Docmode Health (DHTL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹42, Docmode Health carries a market cap of just ₹14 crore. My first rule: never invest in something I can't value. Here the book value is unavailable, debt/equity is unavailable, and P/E is effectively meaningless because the latest quarter's net profit is zero. A business that earns nothing cannot justify a purchase on earnings power. Sales declined 12.59% year-over-year, and ROCE is -0.29%. The 82.69% profit growth looks impressive but starts from a negligible base; it is not evidence of a durable franchise. E-learning can be a decent business, but this is not a quality compounder. There is no evident moat, no dividend, and no meaningful return on capital. Promoter holding at 30.86% is okay, but for a microcap it is not high enough to convince me owners have large skin in the game; combined with insufficient data, it raises governance doubts. The positive: quarterly sales of ₹18 crore dwarf the ₹14 crore market cap, so the company is generating revenue. Yet profitability is missing. Piotroski score of 5 out of 9 is mediocre, not a green light. Current price is well below the 52-week high of ₹125.20, but a falling stock is not automatic bargain. Without book value or debt data, I cannot compute a margin of safety. I would classify this as a speculative turnaround candidate—to be watched, not bought. Intelligent investing requires facts; here there are too few. I'll pass until earnings, balance sheet, and cash flow become transparent.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer